Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy? - PubMed (original) (raw)
Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy?
Amit Agarwal et al. World J Surg. 2010 Dec.
Abstract
Background: Size can predict malignancy in adrenocortical tumors, but the same extrapolation for pheochromocytomas (PCC) is controversial. The goal of this study was to find a correlation between the tumor size and malignant potential of PCC and determine whether the "Pheochromocytoma of the adrenal gland scaled score" (PASS) proposed by Thompson can be applied to predict malignancy.
Methods: A retrospective analysis of patients with PCC operated on from 1991 to 2007 revealed 98 PCC removed from 93 patients. Tumor size was available for 90 tumors. Six (6.4%) patients had proven malignancy. Five familial cases were excluded from the PASS analysis.
Results: Of the benign cases, none developed recurrence or metastasis. There were 54 (60%) tumors > 6 cm and 36 (40%) tumors ≤ 6 cm. All 12 PASS parameters were individually present in higher frequency in the >6-cm group; but the difference was not statistically significant except cellular monotony (p = 0.02). Overall, a PASS ≤ 4 was found in 57 patients. Mean PASS was statistically significantly higher in the >6-cm group (4.4 vs. 3.3, p = 0.04). Of the sporadic benign cases, 21 (41%) patients with tumor size > 6 cm had a PASS of >4, and none of them developed metastasis. PASS ≤ 4 was found in 25 (81%) PCC in the ≤6-cm group, and none developed metastases. PASS ≥ 4 was found in six (19%) patients in the ≤6-cm group, and none developed metastases. 68 patients completed 5-year follow-up, and the remaining had a mean follow-up of 28.7 months. No correlation was found between tumor size and PASS > 4 and PASS ≤ 4 (7.8 cm vs. 7.1 cm; p = 0.23).
Conclusions: Presently there is not enough evidence to indict a large (>6 cm) PCC as malignant. Furthermore, PASS cannot be reliably applied to PCC for predicting malignancy.
Similar articles
- Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
Strong VE, Kennedy T, Al-Ahmadie H, Tang L, Coleman J, Fong Y, Brennan M, Ghossein RA. Strong VE, et al. Surgery. 2008 Jun;143(6):759-68. doi: 10.1016/j.surg.2008.02.007. Epub 2008 Apr 14. Surgery. 2008. PMID: 18549892 Clinical Trial. - Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
Wachtel H, Hutchens T, Baraban E, Schwartz LE, Montone K, Baloch Z, LiVolsi V, Krumeich L, Fraker DL, Nathanson KL, Cohen DL, Fishbein L. Wachtel H, et al. J Clin Endocrinol Metab. 2020 Dec 1;105(12):e4661-70. doi: 10.1210/clinem/dgaa608. J Clin Endocrinol Metab. 2020. PMID: 32877928 Free PMC article. - Malignant pheochromocytoma: new malignancy criteria.
de Wailly P, Oragano L, Radé F, Beaulieu A, Arnault V, Levillain P, Kraimps JL. de Wailly P, et al. Langenbecks Arch Surg. 2012 Feb;397(2):239-46. doi: 10.1007/s00423-011-0850-3. Epub 2011 Nov 9. Langenbecks Arch Surg. 2012. PMID: 22069042 - Incidental adrenal pheochromocytoma. Report on 5 operated patients and update of the literature.
Porcaro AB, Novella G, Ficarra V, D'Amico A, Antoniolli SZ, Curti P. Porcaro AB, et al. Arch Ital Urol Androl. 2003 Dec;75(4):217-25. Arch Ital Urol Androl. 2003. PMID: 15005498 Review. - Advances in the management of adrenal tumors.
Hanna NN, Kenady DE. Hanna NN, et al. Curr Opin Oncol. 2000 Jan;12(1):49-53. doi: 10.1097/00001622-200001000-00008. Curr Opin Oncol. 2000. PMID: 10687729 Review.
Cited by
- Usefulness of the Primary Tumor Standardized Uptake Value of Iodine-123 Metaiodobenzylguanidine for Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma.
Hirahara M, Nakajo M, Kitazano I, Jinguji M, Tani A, Takumi K, Kamimura K, Tanimoto A, Yoshiura T. Hirahara M, et al. Mol Imaging Biol. 2024 Dec;26(6):1005-1015. doi: 10.1007/s11307-024-01952-8. Epub 2024 Sep 18. Mol Imaging Biol. 2024. PMID: 39294365 Free PMC article. - Differences between Patients with Sporadic and Familial Pheochromocytoma-Is It Possible to Avoid Genetic Testing in Certain Patients?
Muñoz MC, Febrero B, Abellán M, Hernández AM, Rodríguez JM. Muñoz MC, et al. Biomedicines. 2024 Jun 18;12(6):1352. doi: 10.3390/biomedicines12061352. Biomedicines. 2024. PMID: 38927559 Free PMC article. - Identification of Predictors of Metastatic Potential in Paragangliomas to Develop a Prognostic Score (PSPGL).
Iguchi DYV, Martins Filho SN, Soares IC, Siqueira SAC, Alves VAF, Assato AK, Yang JH, Almeida MQ, Villares Fragoso MCB, Fagundes GFC, Mendonca BB, Lourenço Junior DM, Hoff AO, Castroneves LA, Ferraz-de-Souza B, Giannella MLCC, Pereira MAA. Iguchi DYV, et al. J Endocr Soc. 2024 May 7;8(7):bvae093. doi: 10.1210/jendso/bvae093. eCollection 2024 May 23. J Endocr Soc. 2024. PMID: 38799767 Free PMC article. - [Metastatic risk factors in pheochromocytoma/paraganglioma].
Rebrova DV, Loginova OI, Vorobyev SL, Vorokhobina NV, Kozorezova ES, Indeykin FA, Savelyeva TV, Sleptsov IV, Chernikov RA, Fedorov EA, Semenov AA, Chinchuk IK, Shikhmagomedov SS, Alekseev MA, Krasnov LM, Rusakov VF. Rebrova DV, et al. Probl Endokrinol (Mosk). 2023 Oct 4;70(2):37-45. doi: 10.14341/probl13331. Probl Endokrinol (Mosk). 2023. PMID: 38796759 Free PMC article. Review. Russian. - Molecular classification and tumor microenvironment characteristics in pheochromocytomas.
Qin S, Xu Y, Yu S, Han W, Fan S, Ai W, Zhang K, Wang Y, Zhou X, Shen Q, Gong K, Sun L, Zhang Z. Qin S, et al. Elife. 2024 Feb 26;12:RP87586. doi: 10.7554/eLife.87586. Elife. 2024. PMID: 38407266 Free PMC article.
References
- Am J Surg Pathol. 2009 Apr;33(4):599-608 - PubMed
- Arch Surg. 1999 Feb;134(2):181-5 - PubMed
- World J Surg. 1990 May-Jun;14(3):325-9 - PubMed
- Am J Surg Pathol. 2002 May;26(5):551-66 - PubMed
- Ann Surg. 1999 Jun;229(6):755-64; discussion 764-6 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical